<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20080826001096N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-08-18</date_registration>
      <primary_sponsor>Research vice-chancellorship, Guilan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of vaginal washing before Misoprostol insertion on ripening cervix before labor induction</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of vaginal washing before Misoprostol insertion on ripening cervix before labor induction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>164</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40234</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible individuals are assigned  blocked randomization size of 4 in sealed envelopes.The patients will be divided into two groups: vaginal washing (A) and control group (without vaginal washing) (B).

Random sequences will be generated by computer software.

After generating the list, each individual will be assigned a dedicated code and will be identified with this code during the study.
The registration and randomization sequence are done by a resident of obstetric and gynecology.
 None of the participating in the study will be aware of the randomization list .
Registration and randomization sequence are done by a third party, Blinding description: None of the participating in the study will be aware of the randomization list and also 
sealed envelopes that are numbered sequentially will be used for allocation concealment the randomization process. and envelope relating to each individual only after confirming the eligibility criteria for entry into study for him and the signature of the consent will be opened form by individual.</study_design>
      <phase>3</phase>
      <hc_freetext>Labor induction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: : Vaginal washing with  normal saline 0.9%(20 cc) is performed once before  Misoprostol insertion (25 micrograms vaginal in the fornix posterior vaginal  ) with a syringe. Intervention 2: Control group: Without vaginal washing, only  Misoprostol suppository will be inserted (25 micrograms vaginal into the fornix posterior vaginal ) .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zakieh Bakhshipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-zahra Hospital, Namjoo Ave., Rasht, Guilan, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>54839- 41446</zip>
        <telephone>+98 131332496</telephone>
        <email>Zakie.march88@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyedeh Hajar Sharami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-zahra Hospital, Namjoo Ave., Rasht, Guilan, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>54839 -41446</zip>
        <telephone>+98 13 3336 9224</telephone>
        <email>sharami@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>pregnant women ages 18 to 40
Having 38 to 40 week pregnancy
Having singleton pregnancy
Having normal fetal heart rate (FHR)
Having cephalic presentation
Not having a ban on normal vaginal delivery (cephalopelvic disproportion)
Having no uterine contractions spontaneously and effectively (less than three contractions in 30 minutes)
Having a Bishop score of less than 6
Estimation of fetal weight less than 4000 grams
Candidates for termination of pregnancy (post-term pregnancy (42 weeks and more), oligohydramnios, decreased fetal movements, abdominal biophysical profile score, maternal diabetes mellitus, intrauterine growth retardation, and preeclampsia)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having sensitivity to known prostaglandin (with questions like skin manifestations, hives and rash, dyspnea and coughing, chest pain and blurred vision after taking prostaglandin)
Having vaginal bleeding
Preterm rupture of membranes
Having a history of previous cesarean section or scar on the uterus
Having fetal anomaly
Having doubts about Chorioamnionitis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O61.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other failed induction of labour</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: : Vaginal washing with  normal saline 0.9%(20 cc) is performed once before  Misoprostol insertion (25 micrograms vaginal in the fornix posterior vaginal  ) with a syringe.</i_keyword>
      <i_keyword>Control group: Without vaginal washing, only  Misoprostol suppository will be inserted (25 micrograms vaginal into the fornix posterior vaginal ) .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Success of labor induction. Timepoint: Post-partum. Method of measurement: Duration from induction to active phase of labor.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The duration of vaginal Misoprostol to successful labor induction. Timepoint: During labor. Method of measurement: hour.</sec_outcome>
      <sec_outcome>Vaginal PH. Timepoint: Before and after vaginal washing. Method of measurement: Nitrazine paper.</sec_outcome>
      <sec_outcome>Duration from induction to end of first stage of labor. Timepoint: During labor until the end of the first stage of labor. Method of measurement: hour.</sec_outcome>
      <sec_outcome>Duration from induction to active phase of labor. Timepoint: During labor until the active phase of labor. Method of measurement: hour.</sec_outcome>
      <sec_outcome>Maternal complications (tachysystole,  hyperstimulation, etc.). Timepoint: During labor. Method of measurement: Patient complaint.</sec_outcome>
      <sec_outcome>Neonatal complications include meconium excretion, Apgar score less than 7, admission to the NICU. Timepoint: During labor until after delivery. Method of measurement: Observations by doctor.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research vice-chancellorship, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-15</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Research vice-chancellorship Building, in front of 17-Shahrivar Hospital, Shahid Siadati St., Namjoo Ave., Rasht, Guilan, Iran Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
